Enalapril Maleate and Hydrochlorothiazide
Brand Names: Vaseretic
Methodology & AI Transparency ⓘ
Enalapril Maleate and Hydrochlorothiazide Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage vaseretic: is indicated for the treatment of hypertension.
- 2 Real-world patient consensus: Tracked across 10 patient dosage logs with a 85% satisfaction benchmark (RxCUI 858828).
- 3 Typical cash cost range: Public pharmacy ledger: $14.93 low cash benchmark vs. $36.93 chain retail average ($0.1588/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Enalapril Maleate and Hydrochlorothiazide: headache (9%), dizziness (8.3%), fatigue (8.1%).
Ask our AI Specialists anything about Enalapril Maleate and Hydrochlorothiazide
Enalapril Maleate and Hydrochlorothiazide Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage vaseretic: is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial treatment . In using VASERETIC, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk .
Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the latter decrease is small, it results in small increases of serum potassium.
Pharmacokinetic profiling of Enalapril Maleate and Hydrochlorothiazide demonstrates an elimination half-life of Biphasic clearance with 8–12 hr terminal t½ under Enalapril Maleate and Hydrochlorothiazide maintenance with Systemic oral bioavailability of roughly 70%–82% following first-pass transit systemic bioavailability; clearance proceeds via hepatic enzymatic processing and renal clearance proportional to creatinine clearance (enalapril maleate and hydrochlorothiazide), reaching clinical onset within initial pharmacodynamic onset within 1–4 hrs (peak cmax) for enalapril maleate and hydrochlorothiazide.
Titration schedules for Enalapril Maleate and Hydrochlorothiazide (5 mg/1 / 12.5 mg/1 Tablet → 10 mg/1 / 25 mg/1 Tablet) require excluding documented intolerance or hypersensitivity reaction involving enalapril maleate and hydrochlorothiazide (thiazide diuretic); concurrent restricted medications flagged in section 4/7 of the enalapril maleate and hydrochlorothiazide dailymed monograph (858828); real-world patient logs highlight headache (9% of reports), dizziness (8.3% of reports), fatigue (8.1% of reports) alongside a 85.00% Worth-It consensus.
Check serum potassium and creatinine periodically if Enalapril Maleate and Hydrochlorothiazide is co-administered with potassium-retaining agents.
Assess baseline hepatic panels and interacting prescriptions when starting Enalapril Maleate and Hydrochlorothiazide (thiazide diuretic).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Enalapril Maleate and Hydrochlorothiazide (thiazide diuretic)
- Concurrent restricted medications flagged in Section 4/7 of the Enalapril Maleate and Hydrochlorothiazide DailyMed monograph (858828)
Logged Side-Effect Incidence (10 Reports)
Enalapril Maleate and Hydrochlorothiazide Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Enalapril Maleate and Hydrochlorothiazide)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Combination of amlodipine and enalapril in hypertensive patients with coronary The fixed combination of enalapril and amlodipine, as well as isolated amlodipine, was effective in the normalization of BP in pts with CAD and SAH stages I and II, adding blockage of the renin-angiotensin system. Arquivos brasileiros de cardiologia • 2009-03-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 19390704 ↗ |
| New Insights on ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in: What a 522-Participant Study Found Compared with telmisartan, enalapril was associated with a higher incidence of cough (8.9% versus 0.8%) and hypotension (3.9% versus 1.1%). The Journal of international medical research • 2002-01-15 • Randomized Controlled Trial | N = 522 | 87/100 | PMID 12526280 ↗ |
| Can This Approach Help? Inside the Latest Research on Radial artery flow-mediated dilatation in heart failure patients: effects of This impairment can be markedly improved by treatments that effectively block the renin-angiotensin system either at ACE or at ACE plus angiotensin receptor level. Hypertension (Dallas, Tex. : 1979) • 2001-12-01 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 11751734 ↗ |
| The real-world benefits and safety of telmisartan vs. Enalapril: Which Works Better for Severe high blood pressure? Both treatment regimens were well tolerated. International journal of clinical practice • 1999-01-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 10665127 ↗ |
| Can This Approach Help? Inside the Latest Research on A comparison study of the echocardiographic changes in hypertensive patients Both drugs interfere with renin-angiotensin aldosterone system, protecting the myocardium from high blood pressure. International journal of cardiology • 2017-03-01 • Randomized Controlled Trial | N = 40 | 82/100 | PMID 28041700 ↗ |
Enalapril Maleate and Hydrochlorothiazide Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1588/unit (~$4.76/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $36.93 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $14.93 / mo | View logs ↓ |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
Enalapril Maleate and Hydrochlorothiazide Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Enalapril Maleate and Hydrochlorothiazide RxNorm Concept ID | 858828 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1588 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $36.93 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $14.93 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 85.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Enalapril Maleate and Hydrochlorothiazide Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Enalapril Maleate and Hydrochlorothiazide integrating DailyMed SPL (2020-08-31), CMS NADAC ($0.1588/unit), and 10 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Enalapril Maleate and Hydrochlorothiazide community threads and patient logs by age, biological sex, dosage, and treatment duration.